首页 > 最新文献

Clinica Chimica Acta最新文献

英文 中文
Biosensing for rapid detection of MDR, XDR and PDR bacteria 用于MDR、XDR和PDR细菌快速检测的生物传感技术。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120121
Samad Rastmanesh , Ilghar Zeinaly , Vahid Alivirdiloo , Ahmad Mobed , Mohammad Darvishi
The emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria poses a significant threat to global public health, complicating the management of infectious diseases and increasing morbidity and mortality rates. Rapid and sensitive detection of these resistant pathogens is crucial for effective treatment and infection control. This manuscript provides a comprehensive overview of various biosensor technologies developed for the rapid identification and quantification of MDR and XDR bacteria. We discuss the principles of operation, sensitivity, specificity, and practical applications of different biosensing platforms, including electrochemical, optical, and piezoelectric sensors. Additionally, we explore recent advancements in nanomaterials and microfluidics that enhance biosensor performance and enable point-of-care testing. The manuscript also addresses the challenges faced in the implementation of these technologies in clinical settings, such as regulatory hurdles and the need for standardization. A systematic literature review was conducted to identify relevant studies. Databases utilized include PubMed and Scopus, covering the time frame from 2015 to 2024. The literature screening criteria focused on the inclusion of only clinically validated studies to ensure the reliability and applicability of the findings. By highlighting the potential of biosensors to revolutionize the detection of drug-resistant bacteria, this work aims to inform researchers, clinicians, and policymakers about the critical role of innovative diagnostic tools in combating antibiotic resistance and improving patient outcomes.
耐多药(MDR)、广泛耐药(XDR)和耐潘德药(PDR)细菌的出现对全球公共卫生构成了重大威胁,使传染病的管理复杂化,并增加了发病率和死亡率。快速灵敏地检测这些耐药病原体对于有效治疗和感染控制至关重要。本手稿全面概述了为快速识别和定量 MDR 和 XDR 细菌而开发的各种生物传感器技术。我们讨论了不同生物传感平台(包括电化学、光学和压电传感器)的工作原理、灵敏度、特异性和实际应用。此外,我们还探讨了纳米材料和微流控技术的最新进展,这些技术提高了生物传感器的性能,实现了床旁检测。稿件还探讨了在临床环境中应用这些技术所面临的挑战,如监管障碍和标准化需求。为确定相关研究,我们进行了系统的文献综述。使用的数据库包括 PubMed 和 Scopus,时间跨度为 2015 年至 2024 年。文献筛选标准侧重于只纳入经过临床验证的研究,以确保研究结果的可靠性和适用性。通过强调生物传感器在彻底改变耐药细菌检测方面的潜力,本研究旨在让研究人员、临床医生和政策制定者了解创新诊断工具在抗击抗生素耐药性和改善患者预后方面的关键作用。
{"title":"Biosensing for rapid detection of MDR, XDR and PDR bacteria","authors":"Samad Rastmanesh ,&nbsp;Ilghar Zeinaly ,&nbsp;Vahid Alivirdiloo ,&nbsp;Ahmad Mobed ,&nbsp;Mohammad Darvishi","doi":"10.1016/j.cca.2024.120121","DOIUrl":"10.1016/j.cca.2024.120121","url":null,"abstract":"<div><div>The emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria poses a significant threat to global public health, complicating the management of infectious diseases and increasing morbidity and mortality rates. Rapid and sensitive detection of these resistant pathogens is crucial for effective treatment and infection control. This manuscript provides a comprehensive overview of various biosensor technologies developed for the rapid identification and quantification of MDR and XDR bacteria. We discuss the principles of operation, sensitivity, specificity, and practical applications of different biosensing platforms, including electrochemical, optical, and piezoelectric sensors. Additionally, we explore recent advancements in nanomaterials and microfluidics that enhance biosensor performance and enable point-of-care testing. The manuscript also addresses the challenges faced in the implementation of these technologies in clinical settings, such as regulatory hurdles and the need for standardization. A systematic literature review was conducted to identify relevant studies. Databases utilized include PubMed and Scopus, covering the time frame from 2015 to 2024. The literature screening criteria focused on the inclusion of only clinically validated studies to ensure the reliability and applicability of the findings. By highlighting the potential of biosensors to revolutionize the detection of drug-resistant bacteria, this work aims to inform researchers, clinicians, and policymakers about the critical role of innovative diagnostic tools in combating antibiotic resistance and improving patient outcomes.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120121"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CRISPR integrated biosensors: A new paradigm for cancer detection
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2025.120179
Arzoo Saini , Neeraj Dilbaghi , Neelam Yadav
Cancer remains one of the leading causes of morbidity and mortality globally, necessitating need for advancements of technologies for early therapeutics. Conventional detection methodologies often lag behind in terms of sensitivity, specificity, and cost-effectiveness, leading to delayed diagnosis and inadequate treatment. The need of advanced diagnostic techniques has considerably increased and led to the development of biosensors. Biosensing technologies offer several advantages over conventional methods hence, overcome limitations and improve diagnostic accuracy. Biosensors, particularly CRISPR-Cas based biosensors have emerged as a revolutionary technology for oncology diagnostics due to their high precision and adaptability. CRISPR-based biosensors provide remarkable precision, sensitivity, multiplexing capabilities, specificity, and rapidness for developing a cost-effective and portable point of care diagnostic device for cancer detection. In this review, we have discussed cancer pathogenicity, assessed the traditional detection techniques, and explored the advancements and advantages of biosensors, particularly CRISPR-based biosensors, in the detection of some major cancer types, namely lung, liver, colorectal, prostate, and cervical cancers. CRISPR-based biosensors represent a significant potential in cancer diagnostics, offering precise, cost-effective, and rapid detection of cancer biomarkers. The integration of CRISPR technology with biosensors holds substantial promise for enhancing early detection and improving patient outcomes in cancer diagnostics.
{"title":"CRISPR integrated biosensors: A new paradigm for cancer detection","authors":"Arzoo Saini ,&nbsp;Neeraj Dilbaghi ,&nbsp;Neelam Yadav","doi":"10.1016/j.cca.2025.120179","DOIUrl":"10.1016/j.cca.2025.120179","url":null,"abstract":"<div><div>Cancer remains one of the leading causes of morbidity and mortality globally, necessitating need for advancements of technologies for early therapeutics. Conventional detection methodologies often lag behind in terms of sensitivity, specificity, and cost-effectiveness, leading to delayed diagnosis and inadequate treatment. The need of advanced diagnostic techniques has considerably increased and led to the development of biosensors. Biosensing technologies offer several advantages over conventional methods hence, overcome limitations and improve diagnostic accuracy. Biosensors, particularly CRISPR-Cas based biosensors have emerged as a revolutionary technology for oncology diagnostics due to their high precision and adaptability. CRISPR-based biosensors provide remarkable precision, sensitivity, multiplexing capabilities, specificity, and rapidness for developing a cost-effective and portable point of care diagnostic device for cancer detection. In this review, we have discussed cancer pathogenicity, assessed the traditional detection techniques, and explored the advancements and advantages of biosensors, particularly CRISPR-based biosensors, in the detection of some major cancer types, namely lung, liver, colorectal, prostate, and cervical cancers. CRISPR-based biosensors represent a significant potential in cancer diagnostics, offering precise, cost-effective, and rapid detection of cancer biomarkers. The integration of CRISPR technology with biosensors holds substantial promise for enhancing early detection and improving patient outcomes in cancer diagnostics.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120179"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Steroid hormone concentrations in dried blood spots: A comparison between capillary and venous blood samples 干血斑中的类固醇激素浓度:毛细管和静脉血样本的比较。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120099
Anouk Olthof , Vera H. de Kleijne , Anita Boelen , Annemieke C. Heijboer

Background

An important aspect of the shift towards dried blood spots (DBS) as a sample matrix for laboratory measurements, is the availability of robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods that can reliably quantify analyte concentrations in DBS. The development and validation of these LC-MS/MS methods, however, concerns an extensive process, for which large amounts of DBS samples are required. DBS are usually obtained from capillary blood samples, but they can also be prepared from venous (residual) blood samples, which are widely available in clinical laboratories. Therefore, we aimed to determine whether DBS prepared from (residual) venous blood samples, collected in EDTA blood tubes, can be used for future development and validation of LC-MS/MS methods to quantify steroid hormones in DBS.

Methods

Capillary DBS and venous blood samples (EDTA tube and tube without additives) were collected from twenty healthy volunteers (12F/8M). From both venous blood samples, DBS were prepared volumetrically. Samples were analyzed using in-house developed LC-MS/MS methods for testosterone, androstenedione, 17-hydroxyprogesterone (17-OHP), cortisol, cortisone, corticosterone, and for dehydroepiandrosterone sulfate (DHEA-S).

Results

DBS made from venous blood collected in EDTA tubes compared with capillary blood showed a correlation coefficient of ≥ 0.89 for all steroid hormones except corticosterone (0.67). DBS made from venous blood collected in tubes without additives showed a strong correlation with both DBS made from venous blood collected in EDTA tubes (≥0.97 for all steroid hormones) and capillary DBS (>0.90) except corticosterone (0.64).

Conclusion

DBS prepared from (residual) venous blood collected in EDTA blood tubes can be used for future development and validation of LC-MS/MS methods to quantify steroid hormones, except for corticosterone, in capillary DBS.
背景:将干血斑(DBS)作为实验室测量的样品基质的一个重要方面是可靠的液相色谱-串联质谱(LC-MS/MS)方法的可用性,该方法可以可靠地定量DBS中的分析物浓度。然而,这些LC-MS/MS方法的开发和验证涉及一个广泛的过程,需要大量的DBS样品。DBS通常从毛细血管血液样本中获得,但也可以从临床实验室广泛使用的静脉(残余)血液样本中制备。因此,我们的目的是确定从EDTA血管中收集的(残余)静脉血样品制备的DBS是否可以用于未来LC-MS/MS方法的开发和验证,以定量DBS中的类固醇激素。方法:采集健康志愿者20例(12F/8M)毛细血管DBS和静脉血(EDTA管和无添加剂管)。从两种静脉血样本中,定量制备DBS。样品采用自行开发的LC-MS/MS方法分析睾酮、雄烯二酮、17-羟基孕酮(17-OHP)、皮质醇、可的松、皮质酮和硫酸脱氢表雄酮(DHEA-S)。结果:EDTA管静脉血与毛细管血DBS的相关系数均为 ≥ ,除皮质酮(0.67)外,其余甾体激素的相关系数均为0.89。无添加剂管静脉血DBS与EDTA管静脉血DBS(所有类固醇激素≥0.97)和除皮质酮(0.64)外的毛细血管DBS(>0.90)均有较强的相关性。结论:EDTA血管中收集的静脉血制备的DBS可用于未来LC-MS/MS方法的开发和验证,用于定量毛细管DBS中除皮质酮外的类固醇激素。
{"title":"Steroid hormone concentrations in dried blood spots: A comparison between capillary and venous blood samples","authors":"Anouk Olthof ,&nbsp;Vera H. de Kleijne ,&nbsp;Anita Boelen ,&nbsp;Annemieke C. Heijboer","doi":"10.1016/j.cca.2024.120099","DOIUrl":"10.1016/j.cca.2024.120099","url":null,"abstract":"<div><h3>Background</h3><div>An important aspect of the shift towards dried blood spots (DBS) as a sample matrix for laboratory measurements, is the availability of robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods that can reliably quantify analyte concentrations in DBS. The development and validation of these LC-MS/MS methods, however, concerns an extensive process, for which large amounts of DBS samples are required. DBS are usually obtained from capillary blood samples, but they can also be prepared from venous (residual) blood samples, which are widely available in clinical laboratories. Therefore, we aimed to determine whether DBS prepared from (residual) venous blood samples, collected in EDTA blood tubes, can be used for future development and validation of LC-MS/MS methods to quantify steroid hormones in DBS.</div></div><div><h3>Methods</h3><div>Capillary DBS and venous blood samples (EDTA tube and tube without additives) were collected from twenty healthy volunteers (12F/8M). From both venous blood samples, DBS were prepared volumetrically. Samples were analyzed using in-house developed LC-MS/MS methods for testosterone, androstenedione, 17-hydroxyprogesterone (17-OHP), cortisol, cortisone, corticosterone, and for dehydroepiandrosterone sulfate (DHEA-S).</div></div><div><h3>Results</h3><div>DBS made from venous blood collected in EDTA tubes compared with capillary blood showed a correlation coefficient of ≥ 0.89 for all steroid hormones except corticosterone (0.67). DBS made from venous blood collected in tubes without additives showed a strong correlation with both DBS made from venous blood collected in EDTA tubes (≥0.97 for all steroid hormones) and capillary DBS (&gt;0.90) except corticosterone (0.64).</div></div><div><h3>Conclusion</h3><div>DBS prepared from (residual) venous blood collected in EDTA blood tubes can be used for future development and validation of LC-MS/MS methods to quantify steroid hormones, except for corticosterone, in capillary DBS.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120099"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of transient elevation of creatinine caused by severe hyperuricemia 一例由严重高尿酸血症引起的肌酐一过性升高。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120110
Qiong Wu , Yumeng Gao , Xinyuan Zhang , Wenbo Cui , Shumin Li , Chunyu Luo , Dianjun Mo , Xinqi Cheng

Background

To explore the underlying causes of significant fluctuations in creatinine levels within three days due to transient and severe uric acid elevation, and to provide evidence for the interpretation of abnormal test results and clinical diagnosis and management.

Methods

The issues were resolved by retesting the samples, comparing results across different detection platforms, and analyzing the reaction curve. We comprehensively reviewed patients’ general conditions, imaging examinations, and treatments. Additionally, we compared pre- and post-admission changes in laboratory indices and performed an extensive literature search for comprehensive analysis.

Results

At the patient’s first visit, the levels of uric acid (UA), creatinine (CR), and urea (UREA) were measured at 891 umol/L, 211 umol/L, and 7.8 mmol/L, respectively using a Roche full-automatic biochemical analyzer and its corresponding reagents. Subsequent testing yielded 917 umol/L, 211 umol/L, and 8.3 mmol/L for UA, CR, and UREA. After retesting with the Beckman automatic biochemical analyzer and its corresponding reagents, the results for UA, CR, and UREA were 1013 umol/L, 221 umol/L, and 7.75 mmol/L, respectively. The results of the two detection systems were in agreement. A supplementary measurement of Cystatin C (CYSC) at 1.69 mg/L indicates renal dysfunction, consistent with the observed increase in CR levels and ruling out false elevation due to assay-related issues. At 48 h post-admission, untreated, the levels of blood UA, CR, and UREA decreased to 567umol/L, 77umol/L, and 5.1 mmol/L, respectively. Through literature review and analysis, it was determined that the transient abnormal increase in the patient’s creatinine level may be attributed to a substantial accumulation of uric acid crystals obstructing the renal tubules, leading to an impediment in renal tubular excretion which subsequently resolves spontaneously.

Conclusion

Severe hyperuricemia may result in a transient increase in blood CR levels and could potentially lead to the development of acute uric acid nephropathy. When a clinical laboratory encounters test results inconsistent with the clinical manifestations, it is essential to not only address any potential detection issues but also proactively investigate the underlying reasons for abnormal test results through comprehensive literature reviews and other rigorous methodologies.
背景:探讨短暂性、重度尿酸升高所致3天内肌酐水平显著波动的潜在原因,为异常检测结果的解释及临床诊断和处理提供依据。方法:通过对样品进行复测,比较不同检测平台的检测结果,分析反应曲线,解决问题。我们全面回顾了患者的一般情况、影像学检查和治疗方法。此外,我们比较了入院前和入院后实验室指标的变化,并进行了广泛的文献检索以进行全面分析。结果:患者首次就诊时,采用罗氏全自动生化分析仪及相应试剂测定尿酸(UA)、肌酐(CR)、尿素(urea)水平分别为891 umol/L、211 umol/L、7.8 mmol/L。随后的测试结果显示UA、CR和尿素分别为917 umol/L、211 umol/L和8.3 mmol/L。经Beckman全自动生化分析仪及相应试剂复测,UA、CR、尿素分别为1013 umol/L、221 umol/L、7.75 mmol/L。两种检测系统的结果是一致的。补充测量胱抑素C (Cystatin C, CYSC)为1.69 mg/L表明肾功能不全,与观察到的CR水平升高一致,排除了由于检测相关问题导致的假升高。入院后48 h,未经治疗,血液UA、CR和尿素水平分别降至567umol/L、77umol/L和5.1 mmol/L。通过文献回顾和分析,确定患者肌酸酐水平的短暂性异常升高可能是由于尿酸晶体大量积聚阻塞肾小管,导致肾小管排泄障碍,随后自行消退。结论:严重的高尿酸血症可导致血液CR水平的短暂升高,并可能导致急性尿酸肾病的发展。当临床实验室遇到与临床表现不一致的检测结果时,不仅要解决任何潜在的检测问题,而且要通过全面的文献综述和其他严格的方法,积极调查检测结果异常的潜在原因。
{"title":"A case of transient elevation of creatinine caused by severe hyperuricemia","authors":"Qiong Wu ,&nbsp;Yumeng Gao ,&nbsp;Xinyuan Zhang ,&nbsp;Wenbo Cui ,&nbsp;Shumin Li ,&nbsp;Chunyu Luo ,&nbsp;Dianjun Mo ,&nbsp;Xinqi Cheng","doi":"10.1016/j.cca.2024.120110","DOIUrl":"10.1016/j.cca.2024.120110","url":null,"abstract":"<div><h3>Background</h3><div>To explore the underlying causes of significant fluctuations in creatinine levels within three days due to transient and severe uric acid elevation, and to provide evidence for the interpretation of abnormal test results and clinical diagnosis and management.</div></div><div><h3>Methods</h3><div>The issues were resolved by retesting the samples, comparing results across different detection platforms, and analyzing the reaction curve. We comprehensively reviewed patients’ general conditions, imaging examinations, and treatments. Additionally, we compared pre- and post-admission changes in laboratory indices and performed an extensive literature search for comprehensive analysis.</div></div><div><h3>Results</h3><div>At the patient’s first visit, the levels of uric acid (UA), creatinine (CR), and urea (UREA) were measured at 891 umol/L, 211 umol/L, and 7.8 mmol/L, respectively using a Roche full-automatic biochemical analyzer and its corresponding reagents. Subsequent testing yielded 917 umol/L, 211 umol/L, and 8.3 mmol/L for UA, CR, and UREA. After retesting with the Beckman automatic biochemical analyzer and its corresponding reagents, the results for UA, CR, and UREA were 1013 umol/L, 221 umol/L, and 7.75 mmol/L, respectively. The results of the two detection systems were in agreement. A supplementary measurement of Cystatin C (CYSC) at 1.69 mg/L indicates renal dysfunction, consistent with the observed increase in CR levels and ruling out false elevation due to assay-related issues. At 48 h post-admission, untreated, the levels of blood UA, CR, and UREA decreased to 567umol/L, 77umol/L, and 5.1 mmol/L, respectively. Through literature review and analysis, it was determined that the transient abnormal increase in the patient’s creatinine level may be attributed to a substantial accumulation of uric acid crystals obstructing the renal tubules, leading to an impediment in renal tubular excretion which subsequently resolves spontaneously.</div></div><div><h3>Conclusion</h3><div>Severe hyperuricemia may result in a transient increase in blood CR levels and could potentially lead to the development of acute uric acid nephropathy. When a clinical laboratory encounters test results inconsistent with the clinical manifestations, it is essential to not only address any potential detection issues but also proactively investigate the underlying reasons for abnormal test results through comprehensive literature reviews and other rigorous methodologies.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120110"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of current patient-based real-time quality control in clinical chemistry testing 临床化学检测中基于患者的实时质量控制现状评价。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120115
Ergin Çam , Deniz İ. Topcu , Alev Kural

Introduction

To perform simulation studies on patient-based real-time quality control (PBRTQC) for aspartate aminotransferase (AST), iron (Fe), potassium (K), and thyrotropin (thyroid stimulating hormone, TSH) analytes, focusing on optimizing systematic error detection while minimizing data loss.

Methods

Clinical laboratory data for the four analytes were analyzed using various truncation methods. Among these methods, truncation limits corresponding to fixed percentiles (e.g., 1st–99th percentiles), reference change value based on between-individual biological variation (RCVg), and truncation limits derived from ± 3 standard deviations from the mean were included. These exclusion methods were applied using trimming or winsorization techniques, and transformation methods (logarithmic, square root, and Yeo–Johnson transformations) were employed to fit the data to a normal or near-normal distribution. Moving average techniques, such as exponentially weighted moving average (EWMA), were used with various block sizes to evaluate systematic error detection performance.

Results

Truncation based on RCVg improved performance for analytes with lower individuality indices—AST, potassium, and TSH—by enabling faster error detection. In contrast, methods either without truncation or with winsorization applied proved to be more effective for Fe. Among the moving average methods, EWMA with smaller block sizes (20 and 30) generally showed superior performance by detecting systematic errors more quickly.

Conclusion

RCVg-based truncation improves error detection for analytes with low individuality when combined with PBRTQC methods like EWMA, minimizing data loss. Tailored strategies considering analyte-specific individuality and distribution are essential for optimal error monitoring, warranting further validation in diverse clinical settings.
简介:对天冬氨酸转氨酶(AST)、铁(Fe)、钾(K)和促甲状腺激素(TSH)分析物进行基于患者的实时质量控制(PBRTQC)模拟研究,重点是优化系统误差检测,同时最大限度地减少数据丢失。方法:采用各种截断方法对四种分析物的临床检验资料进行分析。这些方法包括固定百分位数对应的截断限(例如,第1 -99百分位数)、基于个体间生物变异的参考变化值(RCVg)以及从平均值 ± 3个标准差得出的截断限。这些排除方法使用修剪或winsorization技术,并使用变换方法(对数、平方根和Yeo-Johnson变换)将数据拟合到正态或近正态分布。移动平均技术,如指数加权移动平均(EWMA),用于不同块大小评估系统的错误检测性能。结果:基于RCVg的截断通过更快的错误检测提高了个体指数较低的分析物(ast、钾和tsh)的性能。相比之下,不进行截断或进行去噪处理的方法对Fe更为有效。在移动平均方法中,块大小较小(20和30)的EWMA通常表现出更优的性能,可以更快地检测到系统误差。结论:基于rcvg的截断与EWMA等PBRTQC方法相结合,提高了对低个性分析对象的检错能力,最大限度地减少了数据丢失。考虑到分析物特定的个性和分布,量身定制的策略对于最佳的错误监测至关重要,需要在不同的临床环境中进一步验证。
{"title":"Evaluation of current patient-based real-time quality control in clinical chemistry testing","authors":"Ergin Çam ,&nbsp;Deniz İ. Topcu ,&nbsp;Alev Kural","doi":"10.1016/j.cca.2024.120115","DOIUrl":"10.1016/j.cca.2024.120115","url":null,"abstract":"<div><h3>Introduction</h3><div>To perform simulation studies on patient-based real-time quality control (PBRTQC) for aspartate aminotransferase (AST), iron (Fe), potassium (K), and thyrotropin (thyroid stimulating hormone, TSH) analytes, focusing on optimizing systematic error detection while minimizing data loss.</div></div><div><h3>Methods</h3><div>Clinical laboratory data for the four analytes were analyzed using various truncation methods. Among these methods, truncation limits corresponding to fixed percentiles (e.g., 1st–99th percentiles), reference change value based on between-individual biological variation (RCVg), and truncation limits derived from ± 3 standard deviations from the mean were included. These exclusion methods were applied using trimming or winsorization techniques, and transformation methods (logarithmic, square root, and Yeo–Johnson transformations) were employed to fit the data to a normal or near-normal distribution. Moving average techniques, such as exponentially weighted moving average (EWMA), were used with various block sizes to evaluate systematic error detection performance.</div></div><div><h3>Results</h3><div>Truncation based on RCVg improved performance for analytes with lower individuality indices—AST, potassium, and TSH—by enabling faster error detection. In contrast, methods either without truncation or with winsorization applied proved to be more effective for Fe. Among the moving average methods, EWMA with smaller block sizes (20 and 30) generally showed superior performance by detecting systematic errors more quickly.</div></div><div><h3>Conclusion</h3><div>RCVg-based truncation improves error detection for analytes with low individuality when combined with PBRTQC methods like EWMA, minimizing data loss. Tailored strategies considering analyte-specific individuality and distribution are essential for optimal error monitoring, warranting further validation in diverse clinical settings.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120115"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary miRNAs in bladder cancer
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120113
Amrit Chattopadhaya , Sukhad Kural , Ashish Verma , Priyamvada Gupta , Harshita Tiwari , Swati Singh , Anuja Thakur , Rajiv Kumar , Satya Narayan Sankhwar , Santosh Kumar Singh , Sakshi Agarwal , Sanjana Mehrotra , Vibhav Gautam , Lalit Kumar
Urinary bladder cancer (UBC) is a prominent malignancy with high morbidity and mortality worldwide. Addressing this public health challenge requires the development of effective diagnostic and prognostic indicators. MicroRNAs (miRNAs) are short, non-coding sequences of nucleic acid that modulate gene expression. Due to their high stability in biofluids such as serum, blood and urine, they have become a viable source for non-invasive diagnosis of pathologic processes in general and UBC specifically. This review comprehensively explores the role of urinary miRNAs, both free and exosomal, in the diagnosis, progression, staging, grading, metastasis, recurrence, survival, and treatment of UBC that includes chemo and immunotherapy. Specific miRNAs such as miR-21, miR-126, miR-143, and miR-145 have shown potential as diagnostic markers, whereas others like miR-200 family, miR-34a, miR-125b, and miR-221 are valuable for prognostic and predictive assessment. The review also discusses mechanistic insights into miRNA function and addresses the challenges of translating these findings into clinical practice. It aims to bridge the knowledge gap between academicians, researchers, and medical practitioners by providing a platform to understand, exchange, research, and infer information that could lead to novel therapeutic strategies for UBC. Integration of urinary miRNAs into routine clinical practice could significantly enhance the management of UBC, offering a pathway to personalized medicine and improved patient outcomes, particularly in India, where UBC incidence is increasing.
{"title":"Urinary miRNAs in bladder cancer","authors":"Amrit Chattopadhaya ,&nbsp;Sukhad Kural ,&nbsp;Ashish Verma ,&nbsp;Priyamvada Gupta ,&nbsp;Harshita Tiwari ,&nbsp;Swati Singh ,&nbsp;Anuja Thakur ,&nbsp;Rajiv Kumar ,&nbsp;Satya Narayan Sankhwar ,&nbsp;Santosh Kumar Singh ,&nbsp;Sakshi Agarwal ,&nbsp;Sanjana Mehrotra ,&nbsp;Vibhav Gautam ,&nbsp;Lalit Kumar","doi":"10.1016/j.cca.2024.120113","DOIUrl":"10.1016/j.cca.2024.120113","url":null,"abstract":"<div><div>Urinary bladder cancer (UBC) is a prominent malignancy with high morbidity and mortality worldwide. Addressing this public health challenge requires the development of effective diagnostic and prognostic indicators. MicroRNAs (miRNAs) are short, non-coding sequences of nucleic acid that modulate gene expression. Due to their high stability in biofluids such as serum, blood and urine, they have become a viable source for non-invasive diagnosis of pathologic processes in general and UBC specifically. This review comprehensively explores the role of urinary miRNAs, both free and exosomal, in the diagnosis, progression, staging, grading, metastasis, recurrence, survival, and treatment of UBC that includes chemo and immunotherapy. Specific miRNAs such as miR-21, miR-126, miR-143, and miR-145 have shown potential as diagnostic markers, whereas others like miR-200 family, miR-34a, miR-125b, and miR-221 are valuable for prognostic and predictive assessment. The review also discusses mechanistic insights into miRNA function and addresses the challenges of translating these findings into clinical practice. It aims to bridge the knowledge gap between academicians, researchers, and medical practitioners by providing a platform to understand, exchange, research, and infer information that could lead to novel therapeutic strategies for UBC. Integration of urinary miRNAs into routine clinical practice could significantly enhance the management of UBC, offering a pathway to personalized medicine and improved patient outcomes, particularly in India, where UBC incidence is increasing.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120113"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143173819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An interference in bilirubin detection: Pulmonary marginal zone lymphoma presenting monoclonal cryoglobulin 干扰胆红素检测:肺边缘区淋巴瘤表现单克隆冷球蛋白。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120066
Yi Li , Liangqiong Zhou , Kangyi Wang , Xiaoge Luo , Liqun Zhang , Kaiyong Cai
Marginal zone lymphoma (MZL) of the lung is an indolent B-cell lymphoma. The peripheral blood of most patients with pulmonary MZL contains low or undetectable monoclonal immunoglobulin (M protein) levels. In this case, the clinical laboratory discovered that the pulmonary MZL patient not only associated with high concentration of monoclonal IgG-type protein but also exhibited obvious gel formation characteristics that interfered with clinical biochemistry tests. Thus, the role of M protein in total bilirubin determination was examined in this study. Total bilirubin detection curve difference comparison between monoclonal IgG protein and polyclonal immunoglobulin, interference experiments, and dilution elimination experiments were conducted. These experiments revealed not only a positive correlation between M protein interference in bilirubin detection with its concentration, but also M protein-specific interference distinct from polyclonal immunoglobulin. We employed the R and EmpowerStat statistical systems to evaluate the correlation between serum monoclonal protein and total bilirubin absorbance curve data. Multivariate analysis revealed a nonlinear correlation between with globulin (GLB) and square root transformed curve optical density (OD) data. The receiver operating characteristic (ROC) curve analysis indicated an area under the curve (AUC) of 0.852 for the GLB ≥ 31.9 g/L subgroup using combined curve indicators. Our findings can enhance clinical M protein screening and scientific assessment of the populations requiring serum protein electrophoresis testing, thereby reducing the rate of missed diagnoses in the M protein population.
肺边缘带淋巴瘤(MZL)是一种惰性b细胞淋巴瘤。大多数肺部MZL患者的外周血含有低或检测不到的单克隆免疫球蛋白(M蛋白)水平。在本例中,临床实验室发现肺部MZL患者不仅与高浓度的单克隆igg型蛋白相关,而且表现出明显的凝胶形成特征,干扰了临床生化检查。因此,本研究考察了M蛋白在总胆红素测定中的作用。进行单克隆IgG蛋白与多克隆免疫球蛋白的总胆红素检测曲线差异比较、干扰实验、稀释消除实验。这些实验不仅表明M蛋白对胆红素检测的干扰与其浓度呈正相关,而且表明M蛋白特异性干扰不同于多克隆免疫球蛋白。我们采用R和灌顶统计系统评估血清单克隆蛋白和总胆红素吸光度曲线数据的相关性。多变量分析显示,球蛋白(GLB)与平方根变换曲线光密度(OD)数据之间存在非线性相关。受试者工作特征(ROC)曲线分析显示,GLB ≥ 31.9 g/L亚组的曲线下面积(AUC)为0.852。我们的发现可以加强临床对M蛋白的筛查和对需要进行血清蛋白电泳检测人群的科学评估,从而降低M蛋白人群的漏诊率。
{"title":"An interference in bilirubin detection: Pulmonary marginal zone lymphoma presenting monoclonal cryoglobulin","authors":"Yi Li ,&nbsp;Liangqiong Zhou ,&nbsp;Kangyi Wang ,&nbsp;Xiaoge Luo ,&nbsp;Liqun Zhang ,&nbsp;Kaiyong Cai","doi":"10.1016/j.cca.2024.120066","DOIUrl":"10.1016/j.cca.2024.120066","url":null,"abstract":"<div><div>Marginal zone lymphoma (MZL) of the lung is an indolent B-cell lymphoma. The peripheral blood of most patients with pulmonary MZL contains low or undetectable monoclonal immunoglobulin (M protein) levels. In this case, the clinical laboratory discovered that the pulmonary MZL patient not only associated with high concentration of monoclonal IgG-type protein but also exhibited obvious gel formation characteristics that interfered with clinical biochemistry tests. Thus, the role of M protein in total bilirubin determination was examined in this study. Total bilirubin detection curve difference comparison between monoclonal IgG protein and polyclonal immunoglobulin, interference experiments, and dilution elimination experiments were conducted. These experiments revealed not only a positive correlation between M protein interference in bilirubin detection with its concentration, but also M protein-specific interference distinct from polyclonal immunoglobulin. We employed the R and EmpowerStat statistical systems to evaluate the correlation between serum monoclonal protein and total bilirubin absorbance curve data. Multivariate analysis revealed a nonlinear correlation between with globulin (GLB) and square root transformed curve optical density (OD) data. The receiver operating characteristic (ROC) curve analysis indicated an area under the curve (AUC) of 0.852 for the GLB ≥ 31.9 g/L subgroup using combined curve indicators. Our findings can enhance clinical M protein screening and scientific assessment of the populations requiring serum protein electrophoresis testing, thereby reducing the rate of missed diagnoses in the M protein population.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120066"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanoparticle biosensors for cardiovascular disease detection 用于检测心血管疾病的纳米粒子生物传感器。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120094
Mohamed J. Saadh , Faris Anad Muhammad , Rafid Jihad Albadr , Ashok Kumar Bishoyi , Suhas Ballal , Lakshay Bareja , K.Satyam Naidu , Jasur Rizaev , Waam Mohammed Taher , Mariem Alwan , Mahmood Jasem Jawad , Ali M. Ali Al-Nuaimi
Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.
心血管疾病(cvd)的早期发现和管理对患者的生存和长期健康至关重要。心血管疾病的生物标志物如心肌肌钙蛋白- i (cTnI)、n端前脑利钠肽(NT-proBNP)、肌酸激酶MB (CK-MB)、半乳糖凝集素-3 (Gal-3)等在心肌损伤即急性心肌梗死(AMI)后释放到循环中。包括使用纳米颗粒在内的生物传感器技术可以设计成针对与心血管疾病相关的特定生物标志物,从而实现早期检测和更快速的干预,以降低发病率和死亡率。到目前为止,随着纳米颗粒的结合,一些基于光学和电化学的生物传感器已经成功地用于CVD生物标志物的检测。纳米材料作为电极和金芯片等传感器表面的修饰剂,由于其较大的表面积,可以更全面、更有效地固定捕获分子,即抗体、适体和其他配体。近年来,无机纳米颗粒由于其优异的响应强化、适应性强的功能化化学、形状控制、良好的生物相容性和良好的稳定性而被广泛应用于生物传感器的生产中。本文综述了不同类型纳米颗粒在心血管疾病生物标志物检测中的应用。
{"title":"Nanoparticle biosensors for cardiovascular disease detection","authors":"Mohamed J. Saadh ,&nbsp;Faris Anad Muhammad ,&nbsp;Rafid Jihad Albadr ,&nbsp;Ashok Kumar Bishoyi ,&nbsp;Suhas Ballal ,&nbsp;Lakshay Bareja ,&nbsp;K.Satyam Naidu ,&nbsp;Jasur Rizaev ,&nbsp;Waam Mohammed Taher ,&nbsp;Mariem Alwan ,&nbsp;Mahmood Jasem Jawad ,&nbsp;Ali M. Ali Al-Nuaimi","doi":"10.1016/j.cca.2024.120094","DOIUrl":"10.1016/j.cca.2024.120094","url":null,"abstract":"<div><div>Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120094"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in laboratory diagnosis of Sjogren’s disease in children 儿童干燥病实验室诊断研究进展。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120095
Yuemeng Li , Wenxiu He , Yu Zhou , Haotian Chen , Pengyue You , Danni Mu , Yichen Ma , Yumeng Gao , Kaiduo Xu , Haitao Dong , Xinqi Cheng
Sjogren’s disease (SjD) in children is a rare chronic autoimmune disease not fully recognized due to clinical manifestations different from adults. As such, new objective indicators are needed to supplement existing markers and assist in diagnosis. This review summarizes pathogenesis of SjD in children, current diagnostic criteria and research progress in laboratory diagnosis including serologic testing, saliva and tear analysis, histopathological examination as well as emerging markers of interest.
儿童干燥病(SjD)是一种罕见的慢性自身免疫性疾病,因其临床表现与成人不同而未被充分认识。因此,需要新的客观指标来补充现有的标志物并协助诊断。本文综述了儿童SjD的发病机制、目前的诊断标准和实验室诊断的研究进展,包括血清学检测、唾液和泪液分析、组织病理学检查以及新兴的感兴趣的标志物。
{"title":"Advances in laboratory diagnosis of Sjogren’s disease in children","authors":"Yuemeng Li ,&nbsp;Wenxiu He ,&nbsp;Yu Zhou ,&nbsp;Haotian Chen ,&nbsp;Pengyue You ,&nbsp;Danni Mu ,&nbsp;Yichen Ma ,&nbsp;Yumeng Gao ,&nbsp;Kaiduo Xu ,&nbsp;Haitao Dong ,&nbsp;Xinqi Cheng","doi":"10.1016/j.cca.2024.120095","DOIUrl":"10.1016/j.cca.2024.120095","url":null,"abstract":"<div><div>Sjogren’s disease (SjD) in children is a rare chronic autoimmune disease not fully recognized due to clinical manifestations different from adults. As such, new objective indicators are needed to supplement existing markers and assist in diagnosis. This review summarizes pathogenesis of SjD in children, current diagnostic criteria and research progress in laboratory diagnosis including serologic testing, saliva and tear analysis, histopathological examination as well as emerging markers of interest.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120095"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biosensors for the detection of celiac disease 用于检测乳糜泻的生物传感器。
IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120092
Asma Vafadar , Parisa Vosough , Shayan Khalili Alashti , Saeed Taghizadeh , Amir Savardashtaki
Celiac disease (CeD) is an autoimmune disorder triggered by sensitivity to gluten, a protein complex found in wheat, barley, and rye. Gliadins, a component of gluten, are proteins that trigger an immune response in individuals with CeD, primarily affecting the small intestine’s inner lining. Despite a 1–1.5% prevalence, only 24% of cases are diagnosed due to non-specific symptoms. Screening is advised for high-risk groups, including first-degree relatives and type 1 diabetes patients. The accurate diagnosis of this condition and the assessment of the patient’s response to the current treatment – a lifelong gluten-free diet – necessitate using dependable, swift, sensitive, specific, uncomplicated, and affordable analytical methods. Detecting CeD biomarkers in whole blood, serum, or plasma provides a non-invasive approach that serves as an ideal initial diagnostic step. Biosensors offer a novel and alternative way for CeD detection, began emerging in 2007, and hold promise for clinical and point-of-care applications. This review explores the use of biomarker-based diagnostic approaches for CeD, with a focus on biosensors. It delves into the progress of biosensors for CeD diagnosis, identifying trends and challenges in this evolving field. Key biomarkers are highlighted, offering insights into the evolving landscape of biosensors in CeD detection.
乳糜泻(CeD)是一种自身免疫性疾病,由对麸质(小麦、大麦和黑麦中发现的一种蛋白质复合物)的敏感性引发。麦胶蛋白是谷蛋白的一种成分,是一种在CeD患者体内引发免疫反应的蛋白质,主要影响小肠内壁。尽管患病率为1-1.5%,但只有24%的病例是由于非特异性症状而被诊断出来的。建议对高危人群进行筛查,包括一级亲属和1型糖尿病患者。这种情况的准确诊断和评估患者对当前治疗的反应-终身无麸质饮食-需要使用可靠,快速,敏感,特异性,简单和负担得起的分析方法。在全血、血清或血浆中检测CeD生物标志物提供了一种非侵入性的方法,是理想的初始诊断步骤。生物传感器为CeD检测提供了一种新颖的替代方法,于2007年开始出现,并有望在临床和护理点应用。这篇综述探讨了基于生物标志物的诊断方法在CeD中的应用,重点是生物传感器。它深入研究了生物传感器用于CeD诊断的进展,确定了这一不断发展的领域的趋势和挑战。重点介绍了关键的生物标志物,为生物传感器在CeD检测中的发展前景提供了见解。
{"title":"Biosensors for the detection of celiac disease","authors":"Asma Vafadar ,&nbsp;Parisa Vosough ,&nbsp;Shayan Khalili Alashti ,&nbsp;Saeed Taghizadeh ,&nbsp;Amir Savardashtaki","doi":"10.1016/j.cca.2024.120092","DOIUrl":"10.1016/j.cca.2024.120092","url":null,"abstract":"<div><div>Celiac disease (CeD) is an autoimmune disorder triggered by sensitivity to gluten, a protein complex found in wheat, barley, and rye. Gliadins, a component of gluten, are proteins that trigger an immune response in individuals with CeD, primarily affecting the small intestine’s inner lining. Despite a 1–1.5% prevalence, only 24% of cases are diagnosed due to non-specific symptoms. Screening is advised for high-risk groups, including first-degree relatives and type 1 diabetes patients. The accurate diagnosis of this condition and the assessment of the patient’s response to the current treatment – a lifelong gluten-free diet – necessitate using dependable, swift, sensitive, specific, uncomplicated, and affordable analytical methods. Detecting CeD biomarkers in whole blood, serum, or plasma provides a non-invasive approach that serves as an ideal initial diagnostic step. Biosensors offer a novel and alternative way for CeD detection, began emerging in 2007, and hold promise for clinical and point-of-care applications. This review explores the use of biomarker-based diagnostic approaches for CeD, with a focus on biosensors. It delves into the progress of biosensors for CeD diagnosis, identifying trends and challenges in this evolving field. Key biomarkers are highlighted, offering insights into the evolving landscape of biosensors in CeD detection.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120092"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinica Chimica Acta
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1